scPharmaceuticals Statistics
Share Statistics
scPharmaceuticals has 50.04M shares outstanding. The number of shares has increased by 38.79% in one year.
| Shares Outstanding | 50.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 34.54M |
| Failed to Deliver (FTD) Shares | 217 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 5.92M, so 11.83% of the outstanding shares have been sold short.
| Short Interest | 5.92M |
| Short % of Shares Out | 11.83% |
| Short % of Float | 17.15% |
| Short Ratio (days to cover) | 9.23 |
Valuation Ratios
The PE ratio is -4.41 and the forward PE ratio is -5.38.
| PE Ratio | -4.41 |
| Forward PE | -5.38 |
| PS Ratio | 17.77 |
| Forward PS | 1 |
| PB Ratio | 6.49 |
| P/FCF Ratio | -4.07 |
| PEG Ratio | n/a |
Enterprise Valuation
scPharmaceuticals Inc. has an Enterprise Value (EV) of 281.75M.
| EV / Earnings | -5.14 |
| EV / Sales | 20.73 |
| EV / EBITDA | -6.12 |
| EV / EBIT | -5.09 |
| EV / FCF | -4.75 |
Financial Position
The company has a current ratio of 7.08, with a Debt / Equity ratio of 1.05.
| Current Ratio | 7.08 |
| Quick Ratio | 6.4 |
| Debt / Equity | 1.05 |
| Total Debt / Capitalization | 51.16 |
| Cash Flow / Debt | -1.52 |
| Interest Coverage | -6.82 |
Financial Efficiency
Return on equity (ROE) is -1.47% and return on capital (ROIC) is -71.49%.
| Return on Equity (ROE) | -1.47% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -71.49% |
| Revenue Per Employee | 100.69K |
| Profits Per Employee | -406.00K |
| Employee Count | 135 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.43 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40.83% in the last 52 weeks. The beta is 0.14, so scPharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -40.83% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 4.32 |
| Relative Strength Index (RSI) | 44.61 |
| Average Volume (20 Days) | 433.07K |
Income Statement
In the last 12 months, scPharmaceuticals had revenue of 13.59M and earned -54.81M in profits. Earnings per share was -1.42.
| Revenue | 13.59M |
| Gross Profit | 9.78M |
| Operating Income | -55.40M |
| Net Income | -54.81M |
| EBITDA | -46.06M |
| EBIT | -55.40M |
| Earnings Per Share (EPS) | -1.42 |
Balance Sheet
The company has 46.81M in cash and 40.27M in debt, giving a net cash position of 6.54M.
| Cash & Cash Equivalents | 46.81M |
| Total Debt | 40.27M |
| Net Cash | 6.54M |
| Retained Earnings | -281.35M |
| Total Assets | 125.07M |
| Working Capital | 108.06M |
Cash Flow
In the last 12 months, operating cash flow was -59.24M and capital expenditures -40.00K, giving a free cash flow of -59.28M.
| Operating Cash Flow | -59.24M |
| Capital Expenditures | -40.00K |
| Free Cash Flow | -59.28M |
| FCF Per Share | -1.54 |
Margins
Gross margin is 71.96%, with operating and profit margins of -407.53% and -403.22%.
| Gross Margin | 71.96% |
| Operating Margin | -407.53% |
| Pretax Margin | -403.22% |
| Profit Margin | -403.22% |
| EBITDA Margin | -338.86% |
| EBIT Margin | -407.53% |
| FCF Margin | -436.14% |
Dividends & Yields
SCPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -41.52% |
| FCF Yield | -34.64% |
Analyst Forecast
The average price target for SCPH is $15, which is 338.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 338.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -3.36 |
| Piotroski F-Score | 2 |